Novo Nordisk A/S Class B Net Income

Novo Nordisk A/S Class B (NONOF) currently reports a net income of $120B as of June 2026. That compares with $110B in the prior-year period — up 4.8% year over year. That is above the Healthcare sector average of $17B. Use the charts on this page to explore Novo Nordisk A/S Class B's net income history and peer comparisons.

Novo Nordisk A/S Class B's net income increased from $110B to $120B — a 4.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Novo Nordisk A/S Class B's net income of $120B is higher than the Healthcare sector average of $17B. That is roughly 605.0% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Novo Nordisk A/S Class B reported $120B in net income as of June 2026. That compares with $110B in the prior-year period — up 4.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $120B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $17B. From there, open related valuation or income-statement pages for Novo Nordisk A/S Class B, and consider following NONOF for alerts when major investors trade the stock.